Drug Discovery

Target selection connects a candidate therapy to a disease mechanism. Researchers may focus on a protein or cellular pathway whose activity can be altered, then assess whether compounds act on that target rather than unrelated biology. This focus organizes screening and later evaluation around potency, selectivity, and therapeutic relevance, while also helping clarify how disease processes operate.

Lead optimization converts an initial hit into a more suitable candidate by improving several properties at once. Potency measures how strongly the compound affects its target, whereas selectivity concerns limiting activity on unintended targets. Researchers also consider stability and absorption, distribution, metabolism, and excretion, because these characteristics influence how appropriately a compound behaves during further development.

High-throughput screening examines chemical or biological libraries for compounds that alter target activity. Computational modeling adds a complementary approach for analyzing candidate molecules alongside molecular biology and biochemistry results. Pharmacology then helps relate observed activity to biological effects. Integrating these methods supports movement from tested libraries toward promising hits while connecting molecular measurements with broader biological interpretation.

After a promising hit emerges, the workflow moves into lead optimization rather than directly into human testing. Researchers refine potency, selectivity, stability, and absorption, distribution, metabolism, and excretion profiles, then use preclinical studies to evaluate efficacy and toxicity. Clinical studies follow only afterward, assessing safety and therapeutic benefit in humans.

Preclinical testing examines both efficacy and toxicity before clinical studies begin. Efficacy asks whether a candidate produces the intended biological or therapeutic effect, while toxicity addresses harmful effects. Conducting these evaluations first helps determine whether a lead has sufficient support to advance and identifies limitations that could prevent progression into studies assessing safety and therapeutic benefit in humans.

By examining how compounds alter proteins or cellular pathways, researchers can connect changes in target activity with disease-related biology. Molecular biology, biochemistry, and pharmacology help interpret those effects and clarify disease mechanisms. The resulting knowledge can guide compounds toward prevention, diagnosis, or treatment, linking mechanistic insight with practical medical goals.